Related Experiment Video
Updated: Dec 17, 2025

12:03
Viability Assays for Cells in Culture
Published on: January 20, 2014
47.1K
Selective neuronal vulnerability in Alzheimer's disease.
Zuo-Teng Wang1, Can Zhang2, Yan-Jiang Wang3
1Department of Neurology, Qingdao Municipal Hospital, College of Medicine and Pharmaceutics, Ocean University of China, Qingdao, China.
Ageing Research Reviews
|June 23, 2020
Summary
Alzheimer's disease (AD) progression is driven by neuronal vulnerability. Cell-autonomous mechanisms initiate stressor-related damage, followed by non-cell-autonomous mechanisms, offering new therapeutic insights.
Area of Science:
- Neuroscience
- Pathology
- Cell Biology
Background:
- Alzheimer's disease (AD) is characterized by cognitive and behavioral deficits linked to neuronal vulnerabilities in specific brain regions.
- Understanding these selective neuronal vulnerabilities is crucial for deciphering AD progression.
- Current knowledge on neuronal vulnerability mechanisms in AD remains incomplete.
Purpose of the Study:
- To review and elucidate the cell-autonomous and non-cell-autonomous mechanisms contributing to neuronal vulnerability in Alzheimer's disease.
- To provide a framework for understanding neuronal subgroup vulnerability in AD.
- To identify potential targets for AD prevention and therapy.
Main Methods:
- Literature review focusing on cell-autonomous and non-cell-autonomous mechanisms in AD.
- Analysis of neuronal vulnerability across different brain regions and cell types.
- Synthesis of current research on AD pathogenesis.
Main Results:
- Cell-autonomous mechanisms appear to be the primary initiators of neuronal vulnerability and pathological changes in specific brain areas.
- Non-cell-autonomous mechanisms subsequently mediate the progression of AD pathology.
- Identification of distinct vulnerable neuronal types and brain regions is essential for understanding AD.
Conclusions:
- Cell-autonomous mechanisms initiate AD-related neuronal vulnerability, with non-cell-autonomous mechanisms driving disease progression.
- A deeper understanding of these mechanisms offers a novel perspective on AD prevention and therapeutic strategies.
- Targeting both cell-autonomous and non-cell-autonomous pathways may be key to effective AD treatment.
Related Concept Videos
Alzheimer's Disease: Overview
1.5K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.5K
Alzheimer's Disease: Treatment
667
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
667
Neural Regulation
42.9K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
42.9K

